Zacks Investment Research·1d ago
IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D CostsIovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.
Iovance has successfully transitioned to a commercial-stage biotech following the FDA approval of Amtagvi, with revenue surging 60.6% YoY to $263.5M TTM and reaching $99.3M in 2026Q2.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.05+40.5% vs -$0.08 | $121M+4.7% vs $116M |
Q3 2026 Aug 6, 2026 | -$0.11+17.6% vs -$0.13 | $99M+13.1% vs $88M |
Q2 2026 May 7, 2026 | -$0.19+0.0% vs -$0.19 | $71M-8.2% vs $78M |
Q1 2026 Feb 24, 2026 | -$0.18+18.2% vs -$0.22 | $87M+7.4% vs $81M |
Iovance beat Q3 2026 earnings and revenue estimates as Amtagvi sales top $100 million, margins improve and R&D costs decline.
Iovance Biotherapeutics, Inc., delivered strong Q3 results, with revenues up ~80% YoY and gross margin rising to 60%. IOVA reaffirmed 2026 guidance of $410–$420M revenue, and maintains a robust cash position ($376M) expected to last into 2029. Amtagvi's market-leading durability and expanding treatment center network support its competitive positioning despite intense oncology competition.
Iovance Biotherapeutics, Inc. fell 46% after my downgrade to Hold in September, reflecting over-optimism in valuation. AMTAGVI's (lifileucel) melanoma launch gained momentum, but the NSCLC opportunity appeared overestimated based on Q2 call signals. Recent NSCLC data showed a 24.6% ORR across 69 evaluable patients, slightly below the prior interim readout.
Iovance reaffirms its 2026 revenue outlook as Q3 sales jump 80%, fueled by Amtagvi adoption, improving margins and progress in its cancer pipeline.
Benchmark IOVA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Iovance Biotherapeutics, Inc. (IOVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.04 | $3.59B | -16.62 | 60.6% | -58.19% | -29.71% | — | |
| $1.58 | $200.96M | -2.53 | 14.85% | -123.03% | — | — | |
| $1.84 | $214.47M | -1.83 | -51.24% | -2619.64% | -73.92% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — |
Iovance Biotherapeutics, Inc. (IOVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Iovance Biotherapeutics, Inc. (IOVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Aug 6, 2026·SEC
Jul 2, 2026·SEC
Get notified when IOVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Iovance Biotherapeutics, Inc. (IOVA) stock FAQ — growth, dividends, profitability & financials explained
Iovance Biotherapeutics, Inc. (IOVA) reported $379.0M in revenue over the trailing twelve months. Revenue was $263.5M in fiscal year 2025.
Iovance Biotherapeutics, Inc. (IOVA) grew revenue by 51.3% over the trailing twelve months, compared with the twelve months before.
No. Iovance Biotherapeutics, Inc. (IOVA) reported a net loss of $220.5M over the trailing twelve months.
Iovance Biotherapeutics, Inc. (IOVA) had a return on equity (ROE) of -29.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Iovance Biotherapeutics, Inc. (IOVA) had negative free cash flow of $216.1M over the trailing twelve months.
